April 29, 2008 02:29 ET

DSM expects record year following very strong first quarter

HEERLEN, NETHERLANDS--(Marketwire - April 29, 2008) -

* Organic sales growth 14% due to strong business positions and favorable market conditions.

* EBIT from continuing operations up 22% despite lower US dollar and higher feedstock prices.

* Earnings per share up 42%.

* Execution of Vision 2010 strategy fully on track.

* Resumption of share buy-back program for next EUR 250 million as of 5 May.

* Outlook: 2008 EBIT expected to be EUR 870 million +/- 5%.

Feike Sijbesma, chairman of the DSM Managing Board, made the following comment on the results: 'This has been a very strong quarter for DSM with excellent performances across the company, benefiting from the strength of DSM's positions in its various markets and favorable market conditions. We are conscious of the current less favorable macro-economic outlook, but thus far the conditions seen in Q1 have been sustained into the second quarter. We are now expecting 2008 to be a record year for DSM.'

'The company's strong business performance confirms our belief in DSM's Vision 2010 strategy to focus on Life Sciences and Materials Sciences. The roll-out of the strategy remains firmly on track, as illustrated by the recent acquisition of the leading US biomedical materials company, PTG, and the major capital expenditure plans for DSM Dyneema. We are confident that DSM is well-placed to exploit the opportunities the markets are offering us.'

| in EUR million                              | first quarter |     |
|                                             |  2008 |  2007 | +/- |
| Continuing operations:                      |       |       |     |
| Net sales                                   | 2,331 | 2,124 | 10% |
|                                             |       |       |     |
| Operating profit before depreciation and    |   336 |   294 | 14% |
| amortization (EBITDA)                       |       |       |     |
|                                             |       |       |     |
| Operating profit (EBIT)                     |   236 |   193 | 22% |
| - Nutrition                                 |    79 |    63 | 25% |
| - Pharma                                    |     8 |     8 |  0% |
| - Performance Materials                     |    80 |    75 |  7% |
| - Polymer Intermediates                     |    40 |    31 | 29% |
| - Base Chemicals and Materials              |    48 |    29 | 66% |
| - Other activities                          |   -19 |   -13 |     |
|                                             |       |       |     |
| Discontinued operations (DSM Special        |       |       |     |
| Products):                                  |       |       |     |
| Net sales                                   |    27 |    22 |     |
| Operating profit before depreciation and    |     2 |     1 |     |
| amortization (EBITDA)                       |       |       |     |
| Operating profit (EBIT)                     |     1 |    -1 |     |
|                                             |       |       |     |
| Total DSM:                                  |       |       |     |
| Net sales                                   | 2,358 | 2,146 | 10% |
|                                             |       |       |     |
| Operating profit (EBIT)                     |   237 |   192 | 23% |
|                                             |       |       |     |
| Net profit before exceptional items         |   162 |   128 | 27% |
|                                             |       |       |     |
| Net result from exceptional items           |     - |     - |     |
|                                             |       |       |     |
| Net profit                                  |   162 |   128 | 27% |
|                                             |       |       |     |
| Net earnings per ordinary share in EUR:     |       |       |     |
| - total DSM                                 |  0.95 |  0.67 | 42% |
| - continuing operations                     |  0.95 |  0.68 | 40% |
|                                             |       |       |     |

In this report:

* 'operating profit' (before depreciation and amortization) is understood to be operating profit (before depreciation and amortization) before exceptional items;

* 'net profit' is the net profit attributable to equity holders of Royal DSM N.V.

* 'continuing operations' refers to the DSM operations excluding DSM Special Products.

Net sales

 in EUR million     first quarter
                     2008  2007 difference volumes prices exch. other

Nutrition             652   553        18%     11%    13%   -8%    2%
Pharma                207   197         5%      4%     6%   -5%     -
Performance           601   595         1%      2%     2%   -3%    0%
Polymer               342   315         9%     14%     2%   -7%     -
Base Chemicals and
  Materials           404   348        16%      5%    13%   -2%     -
Other activities      125   116

Total, continuing   2,331 2,124        10%      7%     7%   -5%    1%
Discontinued           27    22

Total               2,358 2,146

Net sales from continuing operations in Q1 2008 increased by 10% compared with Q1 2007. Organic growth was very strong at 14%, which was evenly spread over volumes and prices. Volume growth was particularly strong in the nutrition and caprolactam markets because of firm demand, expanding market shares and an excellent manufacturing performance. Solid price increases were possible in the nutrition and fertilizer markets because of a favorable shift in the demand-supply balance and the differentiation strategy in Nutrition. In the anti-infectives markets there was an improvement from the low prices at the end of last year. A substantial part of the organic growth was offset by much lower exchange rates versus the Euro (e.g. US dollar -13%).

Operating profit

The operating profit from continuing operations amounted to EUR 236 million in the first quarter, which is 22% higher than in the first quarter of 2007. This is in spite of feedstock and energy costs being some EUR 50 million higher, while much lower average currency exchange rates versus the Euro had an effect of some EUR 20 million (after hedging). In addition, the phasing-out of some contracts relating to the acquisition of Roche Vitamins had an effect of around EUR 10 million. On top of this innovation expenditure increased further, as planned. All of this was amply compensated for by substantially higher sales volumes and margins across the portfolio.

Business review by cluster


 in EUR million                                       first quarter
                                                        2008   2007

Net sales                                                652    553
Operating profit before depreciation and amortization    110     94
Operating profit                                          79     63

Sales in this cluster increased by 18%. Higher sales volumes and selling prices were partly offset by the lower exchange rate for the US dollar.

DSM Nutritional Products saw its sales volumes strongly increase compared to Q1 2007 due to market growth and the market-share increase during 2007. Prices were increased due to a more balanced supply-demand situation, especially in vitamin E and vitamin C. Carotenoid prices were somewhat lower than last year. DSM Nutritional Products' operating profit strongly increased as a result of higher volumes and margins despite the negative impact of the US dollar and the phasing-out of the Roche contracts. DSM Food Specialties showed a decrease in net sales and operating profit compared to the high results in Q1 2007, mainly due to lower sales in enzymes and functional foods and the negative impact of the dollar and feedstock costs.


 in EUR million                                       first quarter
                                                        2008   2007

Net sales                                                207    197
Operating profit before depreciation and amortization     23     27
Operating profit                                           8      8

Sales were up 5% due to higher sales volumes and selling prices and despite the weaker US dollar.

The operating profit was equal to Q1 2007, being the balance of a lower result at DSM Pharmaceutical Products and a higher result at DSM Anti-Infectives. The lower result at DSM Pharmaceutical Products was caused by the final phasing-out of Roche contracts and temporarily low sales. At DSM Anti-Infectives the drop in prices that had been experienced at the end of last year turned around, somewhat offset by a weaker US dollar.

Performance Materials

in EUR million                                       first quarter
                                                        2008   2007

Net sales                                                601    595
Operating profit before depreciation and amortization    101     95
Operating profit                                          80     75

Higher sales volumes and higher selling prices (in total 4%) were to a large degree offset by the lower exchange rates for the US dollar and the pound sterling.

The operating profit for the cluster was up 7%. Higher sales volumes and higher margins were partially offset by expansion-related higher fixed costs. DSM Engineering Plastics posted a higher profit because of improved margins due to the fact that selling prices increased and raw-material prices decreased. DSM Dyneema's operating profit increased further due to higher sales enabled by the expanded production capacity. The operating profit of DSM Resins remained at the Q1 2007 level.

Polymer Intermediates

 in EUR million                                       first quarter
                                                        2008   2007

Net sales                                                342    315
Operating profit before depreciation and amortization     46     37
Operating profit                                          40     31

Sales increased by 9%. Higher sales volumes and slightly higher selling prices were partly offset by the weaker US dollar.

Higher sales volumes and margins contributed to the strong increase in Polymer Intermediates' operating profit. The higher sales volumes are based on the excellent production performance of the caprolactam plants, the expanded production capacity for acrylonitrile and solid demand. Due to the tight supply-demand situation, prices were increased further in all markets.

Base Chemicals and Materials

 in EUR million                                       first quarter
                                                        2008   2007

Net sales                                                404    348
Operating profit before depreciation and amortization     65     45
Operating profit                                          48     29

Sales for this cluster were up 16% from Q1 2007, mainly due to higher sales volumes and higher prices and despite the weaker US dollar.

Most businesses in this cluster posted a higher operating profit. DSM Agro sold slightly higher volumes at much higher prices. DSM Melamine improved its margins as selling prices increased more than feedstock costs. The operating profit of DSM Energy increased because of the higher production output and higher prices for oil and natural gas. DSM Elastomers' operating profit decreased as higher sales volumes could not completely compensate for the lower margins caused by higher feedstock costs and the lower US dollar.

Other activities

 in EUR million                                       first quarter
                                                        2008   2007

Net sales                                                125    116
Operating profit before depreciation and amortization     -9     -4
Operating profit                                         -19    -13

The operating profit for Other activities was lower than in Q1 2007. The main reasons were much higher costs for share-based payments (because of the share-price development) and higher innovation expenditure.

Net profit

Net profit increased relative to Q1 2007, from EUR 128 million to EUR 162 million (27%).

Net finance costs amounted to EUR 18 million in Q1 2008. This is slightly above Q1 2007. The impact of a higher net debt was partially offset by lower effective interest rates.

At 25%, the effective tax rate in Q1 2008 was at the level of Q1 2007.

Net earnings per ordinary share increased by 42%, mainly because of the 27% increase in net profit and the reduced number of shares outstanding.

Assets held for sale

During the first quarter DSM announced the intended sale of DSM Special Products to Arsenal Capital Partners. The sale is expected to close in Q2 2008, subject to regulatory approvals. The operating profit of DSM Special Products, previously reported in the Nutrition cluster, improved in Q1 2008, mainly because of higher sales.

Cash flow, capital expenditure and financing

The cash flow (net profit plus depreciation and amortization) in the first quarter of 2008 amounted to EUR 263 million, up EUR 32 million from Q1 2007. At EUR 98 million, capital expenditure (excluding acquisitions) was just below the level of depreciation and amortization (EUR 101 million), but clearly above the level of Q1 2007 (EUR 80 million). The operating working capital as a percentage of net sales was 0.8 percentage point higher than at year-end 2007 due to the seasonal increase following the low level of activity at the end of the year.

Net debt increased by EUR 18 million to EUR 1,356 million in Q1 2008.

Share buy-back program

In September 2007 DSM announced a second EUR 750 million share buy-back program, of which EUR 250 million was realized in the final quarter of 2007. In both programs DSM has, until now, purchased a total amount of EUR 1 billion in shares. DSM has decided to resume the remainder of the second EUR 750 million program on 5 May, for an amount of approximately EUR 250 million, and to review the timing of the buy-back of the final EUR 250 million at the beginning of next year.

This decision is in line with previously communicated cash allocation priorities and is reflecting the increased organic growth opportunities (e.g. the DSM Dyneema investment plan of USD 450 million) and acquisition opportunities (such as the PTG acquisition announced yesterday, but also the continued search for larger acquisitions). Also in view of the situation in the global credit markets DSM has decided to retain prudent financial flexibility.


The workforce increased overall by 110, from 23,254 at year-end 2007 to 23,364 at 31 March 2008. This was the effect of acquisitions and expansions.

Progress update on DSM Strategy Vision 2010

DSM's acceleration of the strategic program Vision 2010 - Building on Strengths, announced in September 2007, focuses on delivering faster growth, higher margins and improved earnings quality from the company's portfolio. The strategy will see the transformation of DSM into a Life Sciences and Materials Sciences company, capable of sustainable growth.

The key drivers for growth - market-driven growth and innovation, increased presence in emerging economies and operational excellence - remain at the heart of DSM's strategy.

In the first quarter several acquisitions following the accelerated Vision 2010 strategy were announced. DSM Resins acquired US-based specialty-resins producer Soluol which makes high performance urethane resins used in a wide range of applications with annual sales of USD 20 million. DSM Resins also acquired Polymeric Processes, Inc., an innovative producer of UV-curable coatings for tube and pipe applications.

DSM Food Specialties acquired CMT Srl in Italy, a company dedicated to the production of the Copan Milk Test.

Yesterday, DSM announced the acquisition of The Polymer Technology Group (PTG) to expand its fast growing biomedical materials business at the crossroads of Life Sciences and Materials Sciences. PTG expects to realize approximately USD 40 million in net sales in 2008 with an above-average operating profit margin.

DSM Venturing announced its first investment in China and also acquired a significant minority stake in IQ Therapeutics BV.

A number of investments aimed at future profitable growth were announced during the quarter such as an investment of EUR 15 million in a new resins plant in Meppen (Germany). More recently DSM announced plans for the largest investment program ever for DSM Dyneema, expected to involve up to USD 450 million. DSM Powder Coating Resins announced a long-term manufacturing plan to expand its polyester powder coating resin facilities.

DSM recently opened a market development plant for PA4T, the first new polymer of the 21st century, for use in electronics and other applications. Since the announcement of PA4T in September 2007, numerous trials at selected customers have been completed. The initial results and customer feedback are very positive and with the opening of the market development plant customer access to PA4T will be extended.

As a result of the accelerated shift towards Life Sciences and Materials Sciences, DSM announced that a number of businesses which do not fit in with the accelerated strategy will be carved out and divested. This process started at the end of 2007. The carve-out is on schedule and is expected to be completed by mid 2008, with the divestment process for the major part commencing thereafter.

During the first quarter, DSM announced the intended sale of DSM Special Products to Arsenal Capital Partners. The sale is expected to close in Q2 2008, subject to regulatory approvals.

During the quarter, DSM introduced and announced many new innovations. The highlights can be found in an appendix to this press release.


DSM experienced strong demand and pricing strength in most of its markets during the first quarter. DSM sees the following trends in its clusters:

* In Nutrition higher sales volumes are expected to be sustained, but growth rates will gradually come down approaching market growth, since market share increased already in the course of 2007. Continued good pricing strength is expected as a result of our successful differentiation activities, higher costs at our competitors and tight supply in several key products.

* In Pharma, the result of DSM Pharmaceutical Products is expected to recover from the weak first quarter. Anti-Infectives' pricing is currently in an upward trend, but is expected to remain on average below last year's level.

* The Performance Materials cluster is developing at a steady positive pace and will benefit from the start-up of several new plants later this year.

* In Polymer Intermediates (also supplying to Performance Materials) there is a tight market, facilitated by a very strong demand, especially in China. DSM does not foresee a short-term shift in these conditions.

* The dominant driver in Base Chemicals and Materials is fertilizers. The prolonged restructuring of the fertilizer industry and currently strong agricultural markets have resulted in a shift in the demand-supply balance, resulting in clearly higher prices.

The current macro-economic outlook is very uncertain. The positive business conditions could be affected by a global negative macro-economic trend. However, in its transformation process to a Life Sciences and Materials Sciences company, DSM has developed a much higher resilience to the business cycle, which is now becoming visible in Nutrition, Performance Materials and Pharma.

As a result DSM remains positive about the remainder of the year, in spite of a weakening US dollar and high feedstock and energy prices.

Based on the currently available information and barring unforeseen circumstances, DSM expects that the operating profit from continuing operations and before exceptional items in 2008 will be EUR 870 million, plus or minus 5%.

Heerlen, 29 April 2008

The Managing Board

Important dates:

Publication of second-quarter         Tuesday, 29 July 2008
Publication of third-quarter results: Monday, 27 October 2008
Annual Report 2008:                   Wednesday, 18 February 2009
Annual General Meeting:               Wednesday, 25 March 2009

DSM - the Life Sciences and Materials Sciences Company Royal DSM N.V. creates innovative products and services in Life Sciences and Materials Sciences that contribute to the quality of life. DSM's products and services are used globally in a wide range of markets and applications, supporting a healthier, more sustainable and more enjoyable way of life. End markets include human and animal nutrition and health, personal care, pharmaceuticals, automotive, coatings and paint, electrics and electronics, life protection and housing. DSM has annual sales of almost EUR 8.8 billion and employs some 23,000 people worldwide. The company is headquartered in the Netherlands, with locations on five continents. DSM is listed on Euronext Amsterdam. More information:

For more information
DSM, Corporate Communications,
Tel. +31 (45) 5782421

DSM Investor Relations
Tel. +31 (45) 5782864

Press release-pdf:

Copyright © Hugin AS 2008. All rights reserved.

Contact Information